Taiwan’s Experience in Managing COVID-19 and the Impact on Medical Students An ounce of prevention is worth a pound of cure.

Main Article Content

Ting-Wei Kao

Abstract

  In the past several months, the globe was overwhelmed by the novel coronavirus (COVID-19) pandemic. As rising number of documented cases and mortality toll continued to be reported, it is imperative to reexamine the current healthcare system as well as consider the repercussion on medical society. The condition in Taiwan, although expected critical regarding close intertwine with epicenter, was relatively stable thus far given multiple efforts paid, suggesting the experiences here may serve as a reference for other countries. In this review, the progression of COVID-19 was illustrated. Additionally, four aspects of implemented measures were introduced, and their respective implications were discussed. First, national team production and name-based allocation, followed by map-directed and online pre-order system, ensured the public to obtain enough surgical masks. Second, constant advocacy of the quarantine policies and personal hygiene, in conjunction with regular press conference by officials, accomplished message transparency and citizens’ literacy upon the situation. Third, establishment of the traffic control bundle successfully antagonized nosocomial infection and prevented subsequent clusters. Forth, biomedical research not only propelled the elucidation of the COVID-19 pathogenesis but also facilitated the development of potential medications and even vaccination. Furthermore, the impact on medical education was delineated. Reorganization of training curriculum, distance learning, and the practice of virtual meeting reshaped the landscape of clinical training. In conclusion, through conscientious appraisal on how we confronted COVID-19 will the community be better prepared for the next pandemic.

Metrics

Metrics Loading ...

Article Details

How to Cite
Kao, T.-W. (2020) “Taiwan’s Experience in Managing COVID-19 and the Impact on Medical Students : An ounce of prevention is worth a pound of cure.”, Journal of Asian Medical Students’ Association. Kuala Lumpur, Malaysia, 8(4), pp. 32-40. Available at: https://j-amsa.amsa-international.org/index.php/main/article/view/183 (Accessed: 26September2020).
Section
Perspective Article

References

[1] Zhu N1, Zhang D1, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
[2] Munster VJ, Koopmans M, van Doremalen N, et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020;382(8):692-4.
[3] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523-34.
[4] Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. Epub ahead of print.
[5] Disease outbreak news (DONs). Geneva: World Health Organization, 2020 (https://www. who.int/csr/don/en/).
[6] WHO Director-General's opening remarks at the media briefing on COVID-19. 11 March 2020.
[7] The COVID-19 Investigation Team. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. MedRxiv preprint.
[8] Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.
[9] Schwartz J, King CC, Yen MY. Protecting Health Care Workers during the COVID-19 Coronavirus Outbreak -Lessons from Taiwan's SARS response. Clin Infect Dis. 2020. Epub ahead of print.
[10] Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. JAMA. 2020. Epub ahead of print.
[11] Hsu YC, Chen YL, Wei HN. Risk and Outbreak Communication: Lessons from Taiwan's Experiences in the Post-SARS Era. Health Secur. 2017 Mar/Apr;15(2):165-9.
[12] Chiu HH, Hsieh JW, Wu YC, et al. Maintaining human health at the border of Taiwan. Biosecur Bioterror. 2014;12(6):346-55.
[13] Yen MY, Lin YE, Lee CH, et al. Taiwan's traffic control bundle and the elimination of nosocomial severe acute respiratory syndrome among healthcare workers. J Hosp Infect. 2011;77(4):332-7.
[14] Fung CP, Hsieh TL, Tan KH, et al. Rapid creation of a temporary isolation ward for patients with severe acute respiratory syndrome in Taiwan. Infect Control Hosp Epidemiol. 2004;25(12):1026-32.
[15] Chen TY, Lai HW, Hou IL, et al. Buffer areas in emergency department to handle potential COVID-19 community infection in Taiwan. Travel Med Infect Dis. 2020. Epub ahead of print.
[16] Yen MY, Schwartz J, Wu JS, et al. Controlling Middle East respiratory syndrome: lessons learned from severe acute respiratory syndrome. Clin Infect Dis. 2015;61(11):1761-2.
[17] Yen MY, Schwartz J, Hsueh PR, et al. Traffic control bundling is essential for protecting healthcare workers and controlling the 2014 Ebola epidemic. Clin Infect Dis. 2015;60(5):823-5.
[18] Kao CC, Chiang HT, Chen CY, et al. National bundle care program implementation to reduce ventilator-associated pneumonia in intensive care units in Taiwan. J Microbiol Immunol Infect. 2019;52:592-7.
[19] Lai CC, Cia CT, Chiang HT, et al. Implementation of a national bundle care program to reduce central line-associated bloodstream infections in intensive care units in Taiwan. J Microbiol Immunol Infect. 2018;51:666-71.
[20] Yen MY, Schwartz J, Chen SY, et al. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: Implications for global prevention and control efforts. J Microbiol Immunol Infect. 2020. Epub ahead of print
[21] World Health Organization. Global surveillance for human infection with coronavirus disease (COVID-19): interim guidance. February 27, 2020.
[22] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar;382(13):1199-1207.
[23] Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020. Epub ahead of print.
[24] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020. Epub ahead of print.
[25] Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214-7.
[26] Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47.
[27] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.
[28] Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. Epub ahead of print.
[29] Lo WL, Lin YG, Pan YJ, et al. Faculty development program for general medicine in Taiwan: Past, present, and future. Tzu Chi Medical Journal. 2014; 26(2):64–67.
[30] Chang WP. Medical education reform in Taiwan: problems and solutions. J Med Education. 2013;17:92–6.
[31] Chu TS, Weed HG, Yang PC. Recommendations for medical education in Taiwan. J Formos Med Assoc. 2009;108:830–3.
[32] Emanuel EJ, Persad G, Upshur R, et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med. 2020. Epub ahead of print.
[33] Bouey J. Strengthening China's Public Health Response System: From SARS to COVID-19. Am J Public Health. 2020:e1-e2.